Coronary stents are permanent metal implants, and after 10 years they are still physically present in your artery. They don’t dissolve, wear out, or need to be replaced on a schedule. But the tissue around them changes significantly over a decade, and those biological changes determine whether the stent continues to work well or starts causing new problems.
How Your Artery Grows Over the Stent
Within weeks of implantation, your artery begins growing a thin layer of tissue over the stent’s metal struts. This process, called endothelialization, essentially buries the stent under a living lining that restores smooth blood flow. With bare-metal stents, this covering is nearly complete within 3 to 4 months. Drug-eluting stents, which release medication to prevent scar tissue from re-narrowing the artery, heal more slowly. Some drug-eluting stent surfaces remain incompletely covered even 40 months after implantation, because the drugs that prevent excessive tissue growth also slow down this protective healing.
Once the stent is fully covered, it becomes a permanent part of the artery wall. The metal scaffold remains structurally intact underneath, providing support, while the tissue layer above it interacts with flowing blood. By the 10-year mark, the stent has long since been incorporated into the vessel wall in most patients.
New Plaque Can Form Inside the Stent
One of the most important things that happens over a decade is the development of new atherosclerosis within the tissue covering the stent. This isn’t the original blockage returning. It’s a distinct process where fresh fatty deposits, driven by inflammation and the body’s ongoing reaction to the foreign metal, accumulate in the tissue layer that grew over the stent struts.
This process, called neoatherosclerosis, follows a predictable pattern. After bare-metal stent placement, arteries typically go through three phases: early narrowing from scar tissue, a middle period where that narrowing partially regresses, and then a late re-narrowing driven by new plaque formation beyond four years. Drug-eluting stents actually develop neoatherosclerosis faster. Research using imaging inside the arteries found that by six years, new plaque had formed in about 38% of one common type of drug-eluting stent and 24% of another, compared to only 10% of bare-metal stents. The drugs that slow initial healing appear to accelerate this later plaque development.
Not all of this new plaque causes symptoms. But when it does progress enough to re-narrow the artery significantly, it can require a repeat procedure.
Risk of Blood Clots Over Time
Stent thrombosis, where a blood clot suddenly forms inside the stent and blocks the artery, is the most dangerous long-term complication. It can cause a heart attack and is a medical emergency. The good news is that with newer-generation drug-eluting stents, this is rare. A large study tracking nearly 6,900 patients with modern stents found that definite stent thrombosis occurred in just 1% of patients over the full 10-year period.
Older-generation drug-eluting stents carried a higher risk, with 3.5% of patients experiencing thrombosis over 10 years. The improvement in newer stents comes from thinner struts, better drug coatings, and polymers that are less likely to provoke chronic inflammation. Even so, the risk of a late clot never drops to zero, which is one reason many patients stay on low-dose aspirin indefinitely after stent placement.
10-Year Outcomes by the Numbers
Large studies tracking patients for a full decade show that drug-eluting stents outperform bare-metal stents on most measures. In one 10-year study of patients with blockages in the main coronary artery, the rate of death or heart attack was 27.9% with drug-eluting stents versus 37.0% with bare-metal stents. The mortality difference was even more striking: 20.6% versus 29.6%.
The biggest practical difference was in repeat procedures. Only 10.2% of drug-eluting stent patients needed another intervention on the same spot, compared to 21.8% of bare-metal stent patients. That means roughly 1 in 10 people with a modern stent will need the treated artery addressed again within a decade, while the figure was closer to 1 in 5 with older technology. These numbers reflect patients with serious coronary disease, so outcomes for people with less severe blockages are generally better.
Stent Fracture
The metal in a stent flexes with every heartbeat, which adds up to hundreds of millions of cycles over a decade. In some cases, this repetitive stress causes the stent to crack. Stent fracture is more common than many patients realize, and the risk increases with time. Fractures can lead to re-narrowing, clot formation, or in cases of complete fracture, small bulges in the artery wall called aneurysms. The clinical significance varies widely. Some fractures are found incidentally on imaging and cause no symptoms, while others trigger chest pain or a heart attack.
What Happens If a Stent Re-Narrows
If your stent does develop significant re-narrowing after several years, the standard treatment is placing a second drug-eluting stent inside the original one. Current guidelines from the major cardiology societies recommend this as the first-line approach. In practice, about 70% of patients with recurrent narrowing receive another stent. Other options include inflating a drug-coated balloon inside the stent without leaving additional metal behind, or using a small rotary device to shave away the excess tissue. Bypass surgery is sometimes considered if the problem recurs multiple times or involves complex anatomy.
What About Dissolvable Stents
Bioresorbable stents were designed to address the concern of having permanent metal in your arteries. These scaffolds, made from a material similar to dissolvable stitches, fully dissolve within about 3 years of placement. The idea was appealing: provide temporary support while the artery heals, then disappear. Clinical follow-up data now extends past 10 years for some patients who received these devices.
In practice, bioresorbable stents had higher rates of complications in the first few years, particularly blood clots, and the main product on the market was withdrawn. Research continues on improved designs, but for now, permanent metal stents remain the standard. If you received a bioresorbable scaffold years ago, the device itself is long gone by the 10-year mark, leaving behind a remodeled artery without any implant.